New antibody drug targets Hard-to-Treat blood cancers
NCT ID NCT06542250
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This study tests an experimental drug called AZD5492 in people with B-cell cancers (like lymphoma or leukemia) that have come back or not responded to at least two prior treatments. The drug works by helping the body's T cells attack cancer cells. The trial will check safety, side effects, and whether the drug shrinks tumors. About 174 adults will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD5492 (a T-cell engaging antibody targeting CD20)
- What this could lead to
- If successful, this could provide a new treatment option for people with B-cell cancers that have not responded to other therapies.
- What could go wrong
- This is an early-phase trial, so safety and effectiveness are not yet proven. Side effects, including immune reactions, are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGLa Jolla, California, 92093, United States
-
Research Site
WITHDRAWNBoston, Massachusetts, 02215, United States
-
Research Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Research Site
RECRUITINGHackensack, New Jersey, 07601, United States
-
Research Site
RECRUITINGNew York, New York, 10021, United States
-
Research Site
RECRUITINGNew York, New York, 10029, United States
-
Research Site
RECRUITINGCharlotte, North Carolina, 28203, United States
-
Research Site
RECRUITINGWinston-Salem, North Carolina, 27157, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGSeattle, Washington, 98109, United States
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
RECRUITINGNedlands, 6009, Australia
-
Research Site
RECRUITINGCalgary, Alberta, T2N 5G2, Canada
-
Research Site
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Research Site
RECRUITINGMontreal, Quebec, H3T 1R2, Canada
-
Research Site
RECRUITINGHangzhou, 310003, China
-
Research Site
RECRUITINGShanghai, 200025, China
-
Research Site
RECRUITINGKøbenhavn Ø, 2100, Denmark
-
Research Site
RECRUITINGPessac, 33604, France
-
Research Site
RECRUITINGVillejuif, 94805, France
-
Research Site
NOT_YET_RECRUITINGGöttingen, DE-37099, Germany
-
Research Site
RECRUITINGMünchen, 81675, Germany
-
Research Site
RECRUITINGUlm, 89081, Germany
-
Research Site
RECRUITINGWürzburg, 97080, Germany
-
Research Site
RECRUITINGBologna, 40138, Italy
-
Research Site
RECRUITINGMilan, 20133, Italy
-
Research Site
RECRUITINGChūōku, 104-0045, Japan
-
Research Site
RECRUITINGKashiwa, 277-8577, Japan
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGL'Hospitalet de Llobregat, 08908, Spain
-
Research Site
RECRUITINGMadrid, 28040, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a single shot build a cancer army inside the body?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
- New combo aims to boost lymphoma control in older patients
- Double-Targeted immune cells take aim at Hard-to-Treat blood cancers